Aster DM Healthcare Limited has informed the Exchange about Transcript
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aster DM Healthcare reported strong Q4 FY26 results with standalone revenue of INR 1,182 crores (up 18% YoY) and operating EBITDA of INR 244 crores (up 26% YoY) with 20.7% margins. On a combined proforma basis with Quality Care India Limited (QCIL), Q4 revenue was INR 2,361 crores with EBITDA of INR 517 crores and margins of 21.9%, while FY26 combined revenue reached INR 9,273 crores. The merger with QCIL received 96.7% shareholder approval and awaits NCLT clearance, expected within the current quarter. Aster India plans to add 2,500 beds over coming years (current capacity: 5,449 beds), while QCIL targets 1,700 beds through INR 2,000 crore investment over 3-4 years. Medical value tourism grew 41% YoY, with CONGO mix (high-complexity care) now at 55% for the combined entity.
The strong Q4 and FY26 results demonstrate consistent operating leverage with margins expanding across clusters, positioning the combined entity well post-merger. The expansion pipeline of 15,000+ beds provides long-term growth visibility while maintaining disciplined capital allocation.